Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.

Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.

Abstract: The invention relates to a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. In addition, it relates to a method for reducing precipitation of an antibody or an antigen-bindmg fragment thereof in a liquid pharmaceutical formulation through addition of methionine and cyclodextrin. In particular, the liquid pharmaceutical formulations comprises an anti-sclerostin antibody, hydroxypropyl-gamma cyclodextrin and methionine and may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength, and especially for treating osteoporosis.

Abstract: The invention relates to a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. In addition, it relates to a method for reducing precipitation of an antibody or an antigen-binding fragment thereof in a liquid pharmaceutical formulation through addition of methionine and cyclodextrin. In particular, the liquid pharmaceutical formulations comprises an anti-sclerostin antibody, hydroxypropyl-gamma cyclodextrin and methionine and may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength, and especially for treating osteoporosis.

Abstract: The present invention relates to pharmaceutical compositions comprising an antibody or a fragment thereof suitable for freeze-drying (i.e. lyophilizing). The pharmaceutical compositions, which comprise an antibody or an antigen-binding fragment thereof; from 1% to 20% w/v sucrose; an amino acid or a mixture of amino acids; and surfactant, are provided as pharmaceutical compositions for freeze-drying; as freeze-dried (i.e. lyophilized) compositions which can be reconstituted into a solvent at the time of use or as reconstituted liquid formulations ready for administration.

Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.

Abstract: The present invention relates to the use of limited amounts of cysteine and tryptophan in the cell culture medium during production of recombinant proteins, and in particular antibodies. Proteins and antibodies produced under such controlled conditions exhibit reduced heterogeneity, in particular reduced charge variants heterogeneity.

Abstract: The present invention relates to pharmaceutical compositions comprising an antibody or a fragment thereof suitable for freeze-drying (i.e. lyophilizing). The pharmaceutical compositions, which comprise an antibody or an antigen-binding fragment thereof; from 1% to 20% w/v sucrose; an amino acid or a mixture of amino acids; and surfactant, are provided as pharmaceutical compositions for freeze-drying; as freeze-dried (i.e. lyophilized) compositions which can be reconstituted into a solvent at the time of use or as reconstituted liquid formulations ready for administration.

Abstract: The invention relates to a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. In addition, it relates to a method for reducing precipitation of an antibody or an antigen-binding fragment thereof in a liquid pharmaceutical formulation through addition of methionine and cyclodextrin. In particular, the liquid pharmaceutical formulations comprises an anti-sclerostin antibody, hydroxypropyl-gamma cyclodextrin and methionine and may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength, and especially for treating osteoporosis.

Abstract: The present invention relates to methods and means for reducing the viscosity of a pharmaceutical formulation comprising an antibody or other therapeutic protein at a high concentration. The present invention provides a liquid pharmaceutical formulation comprising an antibody at a high concentration with reduced viscosity that does not impede processing or injection of the pharmaceutical formulation.